Amirul Fares bin Wan Zahir
Co-Chairman / Director
Fares Zahir who has been the Co-Chairman of MLSCF since July 2008, is the Founder CEO of Xeraya Capital. He has 20 years of experience in the field of investments in public and private equities. Fares was previously with Khazanah Nasional Bhd, where he headed the Life Sciences Unit that formulates investment strategies, and undertakes and monitors the organization's Life Sciences investments, and also headed Khazanah’s Research Unit that undertakes research work in the areas of financial capital markets, industrial organization and economics.
Fares co-founded Xeraya Capital during his tenure in Khazanah together with other team members who collectively provided key input to the Government of Malaysia on incentivizing the Malaysian private sector to invest in risk capital.
He is also a Board member of the Malaysian Technology Development Corporation (“MTDC”), Spring Hill Bioventures and Malaysian Biotechnology Corporation (“Biotech Corp”). In addition, he sits on the Board of investee companies in the US and in Malaysia.
Prior to joining Khazanah in 2005, Fares was Director, Investment Research at UBS Investment Bank where he was a key member of their top rated Malaysian equity research team. From 1996 to 1999, he was Fund Manager with the Schroder Group (also a JV company of the PNB Group) where he managed the Schroder Group's institutional clients’ portfolios after serving as an investment analyst from 1994-1996 making investment recommendations to the Schroder Group's portfolio managers worldwide. Fares started his career in Malaysia in the actuarial department of American International Assurance Co. Ltd. in Kuala Lumpur.
Fares holds a Bachelor of Economics degree in Actuarial Studies from Macquarie University in Australia and a Master of Applied Science in Operations Research from University Technology Sydney. He is also a Chartered Financial Analyst (“CFA”) and an Associate of the Society of Actuaries (“ASA”) of North America.
Roger E. Wyse
Co-Chairman / Director
Dr. Wyse is the Managing Director of Burrill & Company, and has more than 27 years of experience as an internationally recognized plant scientist and business consultant. Prior to joining Burrill & Company in 1998, he had served deanships at Rutgers University and the University of Wisconsin , Madison , where he was Dean of the College of Agricultural and Life Sciences.
Dr. Wyse holds a PhD in Plant Physiology from Michigan State University and is a Fellow of several professional societies. Dr. Wyse served as co-CEO of Third Wave AgBio; was founding President and CEO of Pyxis Genomics, a fully integrated animal genomics company.
He is also the Board Chairman for Chromatin, CreAgri, Efficas, and the Alliance for Animal Genome Research; he is also a member of the Boards of Directors of Cibus Genetics, Emerald BioAgriculture, Pyxis Genomics, Sciona, the Boyce Thompson Institute for Plant Research, and the College of Natural Resources at UC Berkeley.
Norhalim is the CEO of MTDC and is a graduate of Universiti Kebangsaan Malaysia and is a biologist by training. He joined MTDC in 1993, a few months after its inception, and has been instrumental in the commercialisation of research results of local universities and research institutes since then, as well as in the setting up of several start-up and spin-off companies.
Currently, under Norhalim’s supervision, MTDC’s Technology Development Division manages several government technology development programs including Commercialisation of R&D Fund (“CRDF”), Technology Acquisition Fund (“TAF”), Technology Acquisition Fund for Women (“TAF-W”), and technology incubators and garages in three major universities – Universiti Putra Malaysia , Universiti Kebangsaan Malaysia and Universiti Teknologi Malaysia.
Norhalim started his career with Malaysian Oil Palm Growers’ Council in 1987 before moving to Guthrie Plantation & Agricultural Services Sdn Bhd in 1991 as the Assistant Manager responsible for the production and sales of oil palm planting material and agrochemicals, as well as providing technical services to oil palm estates.
Rashidan Shah Abdul Rahim
Rashidan Shah is an Investments Director for Xeraya Capital after joining the company in 2012. He has more than 20 years of experience in the field of investment both in public equities and venture capital. Following his graduation with a degree in accountancy, he started his career as an investment analyst in a fund management company and subsequently between 1991 and 2002, he joined various securities firms as research analyst and dealer. As analyst and later head of research, he specialised in the banking and power sectors and market strategy. In 2002 he was promoted as the Executive Director of Dealing of BBMB Securities and Corporate Nominee on the Kuala Lumpur Stock Exchange (KLSE) representing his Company which was a member company of the KLSE. In 2004, he joined Malaysian Technology Development Corporation as an Assistant General Manager for Investment and led the investment work on various Life Sciences and non-Life Sciences companies both in Malaysia and overseas. He was also involved in the preparation of Malaysia's Biotechnology Plan which led to the setting up of Malaysian Biotech Corporation in 2005. He was also involved in the groundwork and setting up of the Labuan-based Malaysian Life Sciences Capital Fund I which was incorporated in late 2006 and from then onwards utilized some of his time as part of the team in MLSCF. In 2009, he was promoted as a Director for MLSCF and Special Projects Division at MTDC and continued to make new investments for the Company. In 2011, he led the MTDC team to organize the Kuala Lumpur Venture Capital Symposium which saw the participation of many key VC players and thought leaders worldwide.
Mr. Young is an Investment Director at Malaysian Life Sciences Capital Fund. Previously, he held the position of Managing Director within the venture capital division at Burrill & Company, a diversified global financial services firm focused on the life sciences industry. His focus areas of investment cover renewable energy and chemicals, as well as biological processes which promote sustainability. Mr. Young currently serves on the Board of Cobalt Technologies is a Board Observer on the Board of Akermin. Previously, Mr. Young worked as a molecular biologist focused on protein expression at an early-stage biotech company located in San Diego. Mr. Young received his BS in Biochemistry and Cell Biology from the University of California, San Diego and an MS in Biotechnology from Northwestern University.